Latest Breaking News On - D123 - Page 1 : comparemela.com

FOSTER CITY (dpa-AFX) - ImmunoGen, Inc. (IMGN) announced a clinical collaboration with Gilead Sciences, Inc. (GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination

Gilead sciences incMore such health newsImmunogen incGilead sciencesImmunogenWileadValuateIvekimabIthMagrolimabD123PositiveCuteAmyeloidLeukemia